This site is intended for Healthcare Professionals only.

Common cold treatment: Nasal decongestant provides more than symptom relief


Share post:

‘There is no cure for the common cold, but there are ways to alleviate symptoms’

Suffering from a blocked nose due to the common cold? Using a nasal decongestant can alleviate those bothersome nasal symptoms as well as improve your quality of life.

A first-of-its kind study conducted by Haleon found that patients treated with Otrivin 0.1% xylometazoline hydrochloride nasal spray experienced significant improvement in their nasal symptoms as well as their overall well-being and quality of life.

Nasal congestion is not directly caused by the cold virus; rather, it is an inflammatory response to the infection. This symptom typically peaks on the second and third days of the illness, causing sleep disruption, which can lead to drowsiness and affect a person’s mood and overall health.

According to the consumer health company, the non-randomised targeted study was conducted in the UK and involved 102 participants (over 18 years) who were administered the medication as needed for up to seven days.

Significant improvement in nasal congestion was observed among Otrivin users starting from Day 1, enabling them to breathe easily following the nasal spray application.

After the last dose, their overall quality of life scores showed a remarkable 70.4 per cent improvement compared to baseline.

Additionally, the study found a minimum of 70 per cent improvement in sleep quality, vitality, and physical activity measures and 80 per cent improvement in social activity and sensation (taste and smell).

Dr Pranab Kalita, Global Medical Leader, Haleon, warned that the impact of the common cold extends beyond nasal congestion, affecting overall well-being and quality of life.

According to him, this is the first study to evaluate real-life benefits of treating nasal congestion during the common cold with nasal decongestant.

“It confirms not only the effectiveness of xylometazoline hydrochloride 0.1% (Otrivin) in treating nasal congestion during common cold but also demonstrates the significant improvement in overall well-being and quality of life resulting from treatment,” he said.

Fernando Bodalo, VP and Global Brand Lead Respiratory, Haleon, emphasised that while there is no cure for the common cold, there are ways to alleviate symptoms.

“This new real-world study evidences the benefits that products such as Otrivin nasal spray can provide for patients beyond symptom relief.”

There has been an increase in UK hospital admissions over recent months due to a rise in cases of cold and flu cases.

Figures from the NHS showed that 2,226 patients with flu were in hospital each day in the first week of February, three-quarters higher than the same week last January (1,290).

Local pharmacists, who are often the first point of contact for people grappling with the common cold, can provide patients with a way to effectively manage their symptoms and improve their quality of life, thereby reducing pressure on the NHS. This approach will also help pharmacies in managing the growing demand.





Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Head lice cases on the rise across the UK, warns Superdrug

If lotions or sprays prove ineffective, consulting a pharmacist about alternative head lice treatments is recommended Parents are...

Gender identity services: GPhC publishes new resource for pharmacy professionals

The regulatory body sets out questions that pharmacy professionals should ask themselves when providing gender identity care  The General...

NHS patient safety initiative: 143 hospitals across England to roll out Martha’s Rule

This programme has the opportunity to truly transform “patient care and safety” NHS England has confirmed the initial sites...

Why You Shouldn’t Delay in Filing a Medical Malpractice Claim

When faced with the unfortunate situation of medical malpractice, it’s understandable that you may feel overwhelmed and uncertain...